New 9-Valent HPV vaccine aims to shield chinese women from more Cancer-Causing strains
NCT ID NCT03998254
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tests a 9-valent HPV vaccine (V503) in 6,000 Chinese women aged 20-45 to see if it prevents persistent infection and cervical disease from five additional HPV types compared to the current 4-valent vaccine. Participants receive either the new vaccine or Gardasil, and researchers track infections, immune response, and side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
9-valent HPV vaccine (V503)
What this could lead to
If successful, this vaccine could prevent infections and cervical precancers caused by nine HPV types in Chinese women.
What could go wrong
This is a late-stage trial, but results may not apply to all populations. Side effects like injection-site pain or fever are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAPILLOMAVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lingchuan Center for Disease Control and Prevention ( Site 0002)
Guilin, Guangxi, 541200, China
-
Mianyang Center for Disease Control and Prevention ( Site 0005)
Mianyang, Sichuan, 621000, China
-
Quanzhou Center for Disease Control and Prevention ( Site 0001)
Guilin, Guangxi, 541500, China
-
Santai County Center for Disease Control and Prevention ( Site 0006)
Mianyang, Sichuan, 621100, China
-
Xiangyuan Center for Disease Control and Prevention ( Site 0003)
Changzhi, Shanxi, 046299, China
-
Yanhu Center for Disease Control and Prevention of Yuncheng ( Site 0004)
Yuncheng, Shanxi, 044000, China